G protein pathway suppressor 2 (GPS2)

G protein pathway suppressor 2 (GPS2) encodes a multifunctional protein involved in repression of G protein-coupled MAPK signaling. It is an integral part of the NCOR1-HDAC3 transcriptional corepressor complex, inhibiting JNK activation and providing a mechanism for hormone-driven AP1 repression[1][4]. GPS2 is implicated in anti-inflammatory and metabolic regulatory pathways and has emerged as a tumor suppressor, particularly relevant in breast cancer and other malignancies, where its loss leads to unchecked AKT signaling, increased cell proliferation, and tumor growth[2][3]. Monitoring GPS2 status may guide the use of PI3K/AKT inhibitors and hormone therapies in oncology[2][3]. No approved targeted drugs currently directly modulate GPS2, but its role in key signaling networks makes it a potential biomarker and target for future therapeutic strategies.

Other names

GPS2GPS-2AMF-1G protein pathway suppressor 2AMF1

Drugs like MK2206 benefit cancer cells with GPS2 loss by inhibiting the hyperactivated AKT pathway